Parkman Healthcare Partners’s BridgeBio Pharma BBIO Stock Holding History

Parkman Healthcare Partners’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-100,734	Closed	-$4.07M	–	101
2023 Q4	$4.07M	Buy	100,734 +734	+0.7%	+$22K	0.57%	55
2023 Q3	$2.64M	Buy	+100,000	New	+$2.84M	0.48%	61
2021 Q4	–	Sell	-57,978	Closed	-$2.72M	–	86
2021 Q3	$2.72M	Hold	57,978	–	–	0.69%	45
2021 Q2	$3.53M	Sell	57,978 -7,196	-11%	-$411K	0.77%	42
2021 Q1	$4.01M	Sell	65,174 -10,969	-14%	-$718K	0.93%	35
2020 Q4	$5.42M	Buy	76,143 +915	+1%	+$44.1K	1.39%	30
2020 Q3	$2.82M	Buy	75,228 +13	+0%	+$409	0.75%	47
2020 Q2	$2.45M	Hold	75,215	–	–	0.69%	49
2020 Q1	$2.18M	Buy	+75,215	New	+$2.33M	1.01%	33

Other funds holding BBIO

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Parkman Healthcare Partners's BBIO Position: Q1 2024 in Review

Parkman Healthcare Partners sold out of BridgeBio Pharma (BBIO) in Q1 2024, closing a stake of 100,734 shares — an estimated $4.07M sold.

Parkman Healthcare Partners first reported a position in BBIO in Q1 2020 and held it in 9 quarters. The position peaked at $5.42M in Q4 2020. 244 funds tracked by Wall St. Rank hold BBIO as of Q1 2024.

Parkman Healthcare Partners reported no remaining BridgeBio Pharma position as of Q1 2024 after selling out during the quarter.
Parkman Healthcare Partners sold 100,734 BridgeBio Pharma shares in Q1 2024, an estimated $4.07M.
Parkman Healthcare Partners first reported a position in BridgeBio Pharma in Q1 2020 and held it in 9 quarters.
Parkman Healthcare Partners's BridgeBio Pharma position peaked at $5.42M in Q4 2020.
244 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2024.

Based on Parkman Healthcare Partners's 13F filing for Q1 2024, filed 15 May 2024.